Tanzeum
(Albiglutide)PreclinicalPeptide
GSKAlbiglutide is used to help control blood sugar levels in people with type 2 diabetes. It works by helping the pancreas release more insulin when blood sugar is high.[1] Tanzeum is currently being investigated across 1 indication[3], with its most advanced program in Preclinical.[1]
Tanzeum is one of 50 small molecule programs targeting Diabetes Mellitus. It is currently in Preclinical.
1
Indications
29
Total Trials
0
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
113 competitors in Diabetes Mellitus
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Intropin
PfizerApproved
Avelox
BayerApproved
Brilinta
AstraZenecaApproved
Neoral
NovartisApproved
Rifadin
SanofiApproved
Synthroid
IInstitut Jerome Lejeune
Approved
Adipex-P
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Retatrutide
Eli LillyPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes Mellitus10 trials
Show 7 more trials
Type 2 Diabetes8 trials
Show 5 more trials
Tics2 trials
Efficacy and Safety1 trial
6 more indications
Acute Lymphoblastic Leukemia1 trial
Type 1 Diabetes Mellitus1 trial
Nausea1 trial
Oral1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Albiglutide. EMBL-EBI & Wellcome Sanger Institute.
- [4]